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Over a third of the US population is obese and at high risk for developing type 2 diabetes,
insulin resistance, and other metabolic disorders. Obesity is considered a chronic low-
grade inflammatory condition that is primarily attributed to expansion and inflammation of
adipose tissues. Indeed, adipocytes produce and secrete numerous proinflammatory and
anti-inflammatory cytokines known as adipokines.When the balance of these adipokines is
shifted toward higher production of proinflammatory factors, local inflammation within adi-
pose tissues and subsequently systemic inflammation occur. These adipokines including
leptin, visfatin, resistin, apelin, vaspin, and retinol binding protein-4 can regulate inflamma-
tory responses and contribute to the pathogenesis of diabetes.These effects are mediated
by key inflammatory signaling molecules including activated serine kinases such as c-Jun
N-terminal kinase and serine kinases inhibitor κB kinase and insulin signaling molecules
including insulin receptor substrates, protein kinase B (PKB, also known as Akt), and nuclear
factor kappa B. Bariatric surgery can decrease body weight and improve insulin resistance
in morbidly obese subjects. However, despite reports suggesting reduced inflammation
and weight-independent effects of bariatric surgery on glucose metabolism, mechanisms
behind such improvements are not yet well understood. This review article focuses on
some of these novel adipokines and discusses their changes after bariatric surgery and
their relationship to insulin resistance, fat mass, inflammation, and glucose homeostasis.
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INTRODUCTION
Obesity refers to excess fat mass or adiposity, and is typically
defined as a body mass index (BMI) over 30 kg/m2 or a waist
circumference greater than 94 cm for men and 80 cm for women
(Nash et al., 2008). It is a complex multifactorial disease that
is positively associated with increased risk and onset of numer-
ous chronic diseases including cardiovascular disease and Type 2
diabetes (Sjostrom et al., 2004). According to the World Health
Organization report, one billion of the world’s adult popula-
tion is overweight and 300 million of them are obese (Mushtaq
et al., 2011). One of three adults is obese in the United States
(Bhattacharya and Sood, 2011).
The first recommended treatment option for obesity is a low-
calorie diet and regular physical activity. However, these lifestyle
interventions have low compliance in general and limited effec-
tiveness in severely obese people (Hell and Miller, 2002; Yermilov
et al., 2009). Bariatric surgery has emerged as the approach of
choice for weight loss among morbidly obese adults with a BMI
over 40 kg/m2 or those with a BMI over 35 kg/m2 and exist-
ing metabolic risk factors such as hypertension, diabetes, or
hypercholesterolemia (Sjostrom et al., 2004; Kulick et al., 2010).
Recent research has established that obesity is a chronic low-
grade inflammatory condition (Herder et al., 2007; Liu et al.,
2007; Amati et al., 2010; Balistreri et al., 2010; Park et al., 2010;
Thompson et al., 2011). Following bariatric surgery, patients usu-
ally experience approximately 30% weight loss as well as decreased
overall inflammatory responses (Compher and Badellino, 2008).
Concomitantly, there are beneficial changes such as improved
insulin resistance, reduced cardiovascular risk, and decreased
oxidative stress that are achieved through multiple pathways
related to systemic and adipocyte inflammation and adipocyte-
derived cytokines (Cancello et al., 2005; Holdstock et al., 2005;
Mattar et al., 2005; Vazquez et al., 2005; Poitou et al., 2006; Ian-
nelli et al., 2009, 2010; Boesing et al., 2010; Butner et al., 2010;
Hofso et al., 2010; Joao Cabrera et al., 2010; Murri et al., 2010;
Kalupahana et al., 2011, 2012).
BARIATRIC SURGERY
Different types of bariatric surgeries are used for reducing body
weight with various success rates (Franco et al., 2011). In Roux-
en-Y gastric bypass, the stomach is divided into two parts: a small
proximal pouch (15–20 ml) and a large distal pouch (Figure 1A).
The small proximal pouch is attached to the proximal jejunum,
bypassing the large distal gastric pouch and duodenum (Jaunoo
and Southall, 2010). In this procedure energy intake is restricted by
the small volume of the stomach pouch (Arceo-Olaiz et al., 2008;
Yan et al., 2008). Moreover, bypassing the duodenum decreases the
digestion and absorption of food. In vertical banded gastroplasty,
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FIGURE 1 | Bariatric surgery procedures; (A) Roux-n-Y Gastric Bypass, (B) Vertical Gastroplasty, (C) Adjustable Gastric Banding.
the proximal stomach is stapled vertically, allowing food draining
from the proximal pouch to the distal pouch with the outlet rein-
forced with a mesh collar to prevent the enlargement of proximal
pouch and staple line failures (Figure 1B) (Franco et al., 2011).
This procedure decreases the energy intake due to reduced stom-
ach size. However, staple line failures are very common problems
that may lead to regaining of the lost weight (van Hout et al.,
2007). In gastric banding, a cuff band is used to section the stom-
ach into proximal and distal parts (Figure 1C). In the adjustable
form, there is an inflatable balloon in the cuff band. A reservoir can
be placed under the skin and band size can be adjusted by inflating
the balloon from this reservoir (Camerini et al., 2004; Spivak et al.,
2005; Picot et al., 2009). The Roux-en-Y gastric bypass procedure is
more effective for weight loss than the vertical banded gastroplasty
and the adjustable gastric banding (Picot et al., 2009).
INFLAMMATION IN OBESITY
Adipose tissue is considered as an endocrine organ, which consists
of <50% adipocytes and >50% stromal vascular fraction that
contains blood cells, endothelial cells, adipose-tissue precursors
and stem cells, macrophages, and other immune cells (Wang
and Nakayama, 2010). As an endocrine organ, the adipose-
tissue produces and secretes several hormones and cytokines
that play important roles in carbohydrate and lipid metabolism,
inflammation, blood coagulation, as well as satiety, and hunger
signaling (Hajer et al., 2008; Qasim et al., 2008; Wang and
Nakayama, 2010). These cytokines, also known as adipocytokines
or adipokines, are either secreted by adipocytes and/or by the stro-
mal vascular fraction, especially macrophages, as summarized in
Table 1 (Wang and Nakayama, 2010; Gomez-Illan et al., 2012;
Kalupahana et al., 2012). Adipokines can function as classical
cytokines, growth factors and proteins that are involved in blood
pressure regulation, vascular homeostasis, and lipid and glucose
metabolisms (Trayhurn, 2007).
In obesity, expansion of adipose-tissue causes hypoxia and
stress, leading to necrosis of adipocytes. More than 90% of
macrophages in white adipose tissues of animals are local-
ized to dead adipocytes. The “Crown-Like Structure” (Yudkin,
2007) describes necrotic cells with impaired cell integrity and
lipid droplets (Mosser and Edwards, 2008) and the surrounding
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Table 1 | Obesity-associated changes in the levels of common
cytokines secreted by adipocytes and macrophages.
Cytokines Changes Reference
ADIPOCYTE SECRETIONS
Leptin ↑ Oswal and Yeo (2010)
Adinopectin ↓ Asayama et al. (2003)
Visfatin ↑ Sandeep et al. (2007a)
Vaspin ↑ Li et al. (2008)
Apelin ↑ Boucher et al. (2005)
FABP-4 ↓ Queipo-Ortuno et al. (2012)
Perilipin ↓ Wang et al. (2003)
RBP-4 ↑ Wolf (2007)
Resistin ↑ Piestrzeniewicz et al. (2008)
Lipocalin 2 ↑ Catalan et al. (2009)
MACROPHAGE SECRETIONS
IL-6 ↑ Cesari et al. (2005)
TNF-α ↑ Tzanavari et al. (2010)
HGF ↑ Bell et al. (2006)
IL-10 ↓ Blüher et al. (2005)
IL-18 ↑ Leick et al. (2007)
PAI-1 ↑ Cesari et al. (2005)
CRP ↑ Park et al. (2005)
MCP-1 ↑ Panee (2012)
VEGF ↑ Garcia de la Torre et al. (2008)
FABP-4, Fatty Acid Binding Protein-4; RBP-4, Retinol Binding Protein-4; IL-6, Inter-
leukin 6;TNF-α,Tumor necrosis factor-alpha; HGF, HepatocyteGrowth Factor; IL-10,
Interleukin 10; IL-18, Interleukin 18; PAI-1, Plasminogen activator inhibitor-1; CRP,
C-reactive Protein; MCP-1, Monocyte Chemoattractant Protein-1; VEGF, Vascular
Endothelial Growth Factor.
macrophages that serve as scavengers of cell debris and lipid
droplets in the necrotic cells.
There are two types of macrophages in white adipose tissues:
proinflammatory M1 type and anti-inflammatory M2 type (Rull
et al., 2010). M1 type macrophages are mainly recruited and
induced by proinflammatory cytokines produced by expanded
adipose tissue. After M1 type macrophages infiltrate into the adi-
pose tissue, they secrete more proinflammatory cytokines and
produce reactive oxygen species (ROS), which can recruit more
macrophages and amplify the inflammatory response. M2 type
macrophages are adipose-tissue resident macrophages (Rull et al.,
2010). These macrophages are also called as alternatively activated
macrophages because they are activated by interleukin (IL)-4. M2
type macrophages secrete anti-inflammatory cytokines and have
mannose receptors, scavenger receptors and distinct integrins,
which lead to anti-inflammatory functions (Mosser and Edwards,
2008; Rull et al., 2010). With stress and hypoxia in expanded
adipose-tissue during obesity,M2 type macrophages lose their IL-4
receptor expression and IL-4-mediated anti-inflammatory func-
tions, and instead are differentiated into M1 type proinflammatory
macrophages (Rull et al., 2010). Besides IL-4, decreased expres-
sion of IL-10, Ym1, Arginase-1, and increased expression of tumor
necrosis factor-alpha (TNF-α) and inducible nitric oxide syn-
thetase (iNOS) induce the switch of adipose-tissue macrophages
from a M2 to M1 phenotype.
This switch increases the number of proinflammatory
macrophages, resulting in increased production of cytokines
and chemokines including monocyte chemoattractant protein
(MCP)-1, MCP-2, Regulated upon Activation, Normal T cell
Expressed and Secreted (RANTES), and chemokine receptors like
CCR2 and CCR5 (Wang and Nakayama, 2010). These inflamma-
tory chemokines further increase macrophage infiltration to the
adipose tissue (Malavazos et al., 2005; Trayhurn, 2005).
Kanda et al. found that macrophages and endothelial cells in
rat adipose tissue can secrete MCP-1. This chemokine and its
receptor CCR2 direct the migration of monocytes into the adi-
pose tissue. Subsequent exposure of the monocytes to macrophage
colony-stimulating factor causes differentiation to macrophages,
which can secrete more MCP-1 (Kanda et al., 2006). In another
study, obese subjects had significantly higher plasma MCP-1 levels
than lean subjects, and increased plasma MCP-1 levels were pos-
itively associated with insulin resistance (Catalan et al., 2007). In
expanded adipose tissue, M1 type macrophages secrete not only
MCP-1, but also other proinflammatory cytokines including TNF-
α, IL-6, IL-1, IL-1β, and IL-8, which can amplify inflammatory
responses (Coppack, 2001; Zeyda and Stulnig, 2009).
THE ROLES OF INFLAMMATION ON INSULIN SIGNALING
The major regulators in the insulin signaling pathway are insulin
receptor substrates (IRSs). The binding of insulin to its receptor
leads to tyrosine phosphorylation of the receptor. This phospho-
rylation is recognized by the IRS family that has 6 member pro-
teins, IRS1 to IRS6. IRS1 plays an important role in transmitting
signals from the insulin receptor on cell membrane to intracel-
lular phosphatidiylinositol-3-kinase (PI3K)/Akt and extracellular
signal-regulated kinases (Erk)/mitogen-activated protein kinase
(MAPK) pathways (Cai et al., 2003; Tarantino and Caputi, 2011).
Under normal circumstance, the binding of insulin to the insulin
receptor induces a conformational change of the receptor, which
leads to autophosphorylation of specific tyrosine residues in the
cytoplasmic domains of the receptor and further recruitment of
adapter proteins IRSs (Nieto-Vazquez et al., 2008). After interact-
ing with IRSs, PI3K is activated. PI3K lipid products can further
recruit and activate Akt through phosphorylation on threonine
308 (T308) (Nieto-Vazquez et al., 2008). Akt is an important
component of insulin signaling pathways. IRS1 tyrosine phospho-
rylation leads to a second wave of phosphorylation in the Akt
protein. Phosphorylated Akt then initiates more phosphorylation
reactions and eventually leads to glucose uptake, glycogen synthe-
sis, protein synthesis, cell survival and gene transcriptions (Siddle,
2011) (Figure 2). Tyrosine phosphorylation is required for IRS1
activation and insulin sensitization, which are blocked by serine
phosphorylation on IRS1.
Increased production of TNF-α in expanded adipose-tissue
decreases insulin sensitivity (Fantuzzi, 2008). TNF-α binds to
TNF receptor-1 (TNFR1) and activates serine kinases including
c-Jun N-terminal kinase (JNK), serine kinases inhibitor κB kinase
(IKK) and S6 kinase (S6K). These serine kinase can cause serine
phosphorylation of IRS1, block activation of downstream sig-
naling molecules, and further decrease insulin sensitivity (Fain,
2010) (Figure 2). JNK and IKK are important components of the
activator protein-1 (AP-1) and nuclear factor kappa B (NF-kB)
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FIGURE 2 | Effects ofTNP-α on insulin signaling pathways. Insulin
signals tyrosine phosphorylation of IRS and activates SOS (Son of
Sevenless) and the downstream Erk pathway, leading to transcription and
growth. In addition, insulin-stimulated Akt phosphorylation leads to glucose
uptake, glycogen synthesis, protein synthesis, cell survival and gene
transcription. The binding of TNF-α to its receptor increases SOCS-3
expression and activates serine kinases including INK and IKK, which inhibit
IRS tyrosine phosphorylation and activation.
cascade, respectively (Dhanasekaran and Johnson, 2007; Israel,
2010). NF-kB cascade includes a series of transcription factors that
are sequestered by inhibitor of kappa B (IkB) proteins in the cyto-
plasm under normal conditions. IkB kinase (IKK), an important
kinase in the NF-kB cascade, can phosphorylate and inactivate
IkB proteins, and activate NF-kB (Israel, 2010). Proinflamma-
tory cytokines like TNF-α can bind to its cell membrane receptor
(TNFR1), activate IKK, further phosphorylate and inactivate IkB
proteins (Israel, 2010). Subsequently, active NF-kB can translocate
into the nucleus, bind on the promoter regions of cytokine genes,
and stimulate proinflammatory cytokine expression (Ndisang,
2010). TNF-α also increases the expression of cytokine signaling
(SOCS)-1 and SOCS-3 proteins, which can inhibit tyrosine phos-
phorylation of IRS1 and induce ubiqutinylation and degradation
of IRS1 (Figure 2). The expression of SOCS-1 and SOCS-3 is also
stimulated by IL-6. SOCS-3 blunts hepatocyte insulin signaling by
binding to insulin receptors and leading to degradation of IRS pro-
teins (Rasouli and Kern, 2008; Balistreri et al., 2010). In the absence
of SOCS-3, IL-6 can have somewhat anti-inflammatory properties
(Johnston and O’Shea, 2003). Increased plasma IL-6 concentra-
tions are associated with insulin resistance (Charles et al., 2011).
In addition, nitric oxide (NO), an endogenous signaling molecule
produced by iNOS, can reduce Akt activity (Rasouli and Kern,
2008).
TNF-α and IL-6 can also alter the protein expression of per-
oxisome proliferator-activated receptor (PPAR)-γ in adipocytes
(Leff et al., 2004; Tilg and Moschen, 2008; Zhou et al., 2008;
Fernandez-Veledo et al., 2009). PPARγ is an anti-inflammatory
nuclear protein with insulin sensitizing functions (Fernandez-
Veledo et al., 2009). PPARγ blunts inflammatory responses and
stimulates a switch of adipose-tissue macrophages from a M1
to M2 phenotype (Zeyda and Stulnig, 2009). PPARγ can inhibit
the NF-kB signaling pathway, which is an insulin desensitizing
pathway because it activates serine kinases and up-regulates the
production of proinflammatory cytokines like TNF-α and IL-6
(Sidhu et al., 2003). However, JNK and IKK serine kinases can
induce NF-kB activation and further increase TNF-α and IL-6
production, resulting in the suppression of PPARγ in adipocytes
(O’Rourke, 2009). This suppression blunts PPARγ insulin sensi-
tizing functions and leads to insulin resistance via the up-regulated
NF-kB signaling pathway (Sidhu et al., 2003). Other than the
serine kinases, saturated fatty acids can activate the NF-kB sig-
naling pathway by binding to toll-like receptor 2 (TLR2) and 4
(TLR4) in adipocytes. TLR2 and TLR4 are important receptors
of the immune system. Saturated fatty acids can bind to TLRs as
their ligands and increase proinflammatory cytokine production
(Jagannathan et al.,2010). Activation of TLR2 and TLR4 eventually
contributes to insulin resistance via activating the NF-kB signal-
ing pathway and increasing proinflammatory cytokine production
(Monteiro and Azevedo, 2010).
C-reactive protein (CRP), an acute phase protein, is primarily
synthesized in the liver and plays an important role in regulat-
ing the innate immune system (Eisenhardt et al., 2009). CRP
aggravates the inflammatory status and leads to systemic inflam-
mation (Wang and Nakayama, 2010). Plasma CRP levels are cor-
related with circulating levels of other inflammatory biomarkers
(Kones, 2010). There is also a strong positive correlation between
plasma CRP levels and insulin resistance (Pradhan et al., 2003;
Pfutzner and Forst, 2006). Hepatic synthesis of CRP is driven
at the transcriptional level by IL-6, which is mainly secreted by
macrophages, T cells, and adipocytes (Pfutzner and Forst, 2006;
Pfutzner et al., 2006). Since CRP mRNA levels rise in expanded
adipose tissue, it has been proposed that adipose cells also have
some ability to synthesize CRP (Memoli et al., 2007).
THE CHANGES OF NOVEL ADIPOKINES AFTER BARIATRIC
SURGERY AND THEIR RELATIONSHIP TO INSULIN
RESISTANCE
Other than the classic cytokines and chemokines such as TNF-
α, MCP-1, and IL-6, adipocytes also secrete leptin, adiponectin,
visfatin, resistin, omentin, apelin, vaspin, perilipin, adipsin, and
retinol binding protein-4. All these adipokines can contribute
to systemic inflammation and pathogenesis of obesity-associated
complications (Balistreri et al., 2010). An evidence-based review
by Spector and Shikora (2010) attributed the bariatric surgery-
induced insulin sensitization to surgery-specific, metabolic effects
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on glucose homeostasis that are independent of weight loss. How-
ever, the underlying mechanisms are not yet understood. This
review article focuses on novel adipokines including visfatin,
resistin, apelin, vaspin, and retinol binding protein-4 (RBP-4)
and addresses their changes after bariatric surgery and their
relationship to insulin resistance (Table 2).
VISFATIN
Visfatin is produced and secreted mainly by adipocytes in visceral
adipose tissue (Tokunaga et al., 2008). Visfatin is also produced by
a variety of cells including lymphocytes, monocytes, neutrophils,
and hepatocytes (Kukla et al., 2011). This peptide adipokine pro-
duces insulin-mimetic effects by binding to the insulin receptor.
The binding and further activation of the insulin signaling path-
way can stimulate glucose uptake and increase insulin sensitivity
(Fukuhara et al., 2005; Tilg and Moschen, 2006; Sun et al., 2007;
Tokunaga et al., 2008; Fain, 2010). Visfatin and insulin bind to
the different sites of the same insulin receptor (Tilg and Moschen,
2006). This difference in binding sites allows visfatin and insulin
to work non-competitively. Similar to insulin, visfatin stimulates
the phosphorylation of IRS1, IRS2, PI3K binding to IRSs, and acti-
vation of Akt and further promotes insulin sensitivity (Fukuhara
et al., 2005; Adya et al., 2008a; Tan et al., 2009). Some studies
suggested that NF-kB, JNK, and AP-1 upregulate visfatin pro-
duction (Kim et al., 2007, 2008; Adya et al., 2008b; McGee et al.,
2011).
There are many inconclusive data regarding the relationship
between serum visfatin levels and body fat percentage or insulin
resistance. Several studies suggest that blood visfatin levels are sig-
nificantly related to type 2 diabetes or insulin resistance, but not to
body fat percentage or BMI (Sandeep et al., 2007a; Palin et al., 2008;
Retnakaran et al., 2008). One study compared plasma visfatin
levels between type 2 diabetes subjects and non-diabetic healthy
subjects and found that type 2 diabetes subjects had higher serum
visfatin levels than non-diabetic healthy subjects (Sandeep et al.,
2007b). However, this positive correlation between serum visfatin
levels and diabetes status was no longer significant after adjust-
ing for anthropometrics such as BMI and waist circumference
(Dogru et al., 2007; Alghasham and Barakat, 2008; Retnakaran
et al., 2008). In contrast, other studies reported that serum visfatin
Table 2 |The origin and roles of some novel adipokines in inflammation and insulin signaling and their responses to obesity, insulin resistance
and bariatric surgery.
Adipokine Origin Roles in
inflammation
Roles in
insulin signaling
Response to
obesity
Response to
insulin
resistance
Response to
bariatric surgery
Visfatin Visceral adipose
tissue,
lymphocytes,
monocytes,
neutrophils,
hepatocytes
Inflammation
stimulates its
production (Kim
et al., 2007)
Insulin-mimetic
effects via binding to
the insulin receptor
and further activating
IRSs, PI3K and Akt
(Fukuhara et al., 2005)
Inconclusive (Dogru
et al., 2007;
Botella-Carretero
et al., 2008)
Inconclusive (Dogru
et al., 2007;
Alghasham and
Barakat, 2008;
Retnakaran et al.,
2008)
Elevated
(Botella-Carretero
et al., 2008)
Resistin Visceral adipose
tissue
Proinflammatory
effects via activating
NF-kB (Maenhaut
and Van de Voorde,
2011)
Insulin desensitizing
effects via activating
NF-kB and SOCS-3
(Steppan et al., 2005)
Elevated (Moschen
et al., 2009)
Inconclusive (Iqbal
et al., 2005, Sentinelli
et al., 2002; Lee et al.,
2003)
Inconclusive (Iqbal
et al., 2005;
Marantos et al.,
2011)
Apelin Central nervous
system, adipose
tissue, heart,
kidneys, liver, brain
Unknown Insulin sensitizing
effects via activating
AMPK, PI3K and Akt
(Attane et al., 2011)
Elevated but not
entirely due to
obesity (Boucher
et al., 2005;
Castan-Laurell et al.,
2011)
Elevated (Boucher
et al., 2005; Soriguer
et al., 2009; Dray
et al., 2010; Yu et al.,
2012)
Decreased (Soriguer
et al., 2009)
Vaspin Visceral adipose
tissue,
subcutaneous
adipose tissue
Unknown Insulin sensitizing
effects (Kloting et al.,
2006)
Elevated (Youn et al.,
2008; Chang et al.,
2010)
Elevated (Ye et al.,
2009; Kempf et al.,
2010)
Decreased (Chang
et al., 2010;
Handisurya et al.,
2010)
RBP-4 Adipose tissue,
liver
Unknown Inhibits PI3K and IRS
activation, and GLUT4
protein expression
(Wolf, 2007; Esteve
et al., 2009)
Mostly elevated
(Yao-Borengasser
et al., 2007; Bajzova
et al., 2008;
Gomez-Ambrosi
et al., 2008)
Elevated (Graham
et al., 2006; Esteve
et al., 2009)
Decreased (Janke
et al., 2006; von
Eynatten et al., 2007;
Bajzova et al., 2008)
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levels were significantly associated with obesity even after adjust-
ing for age, sex, and diabetes (Fukuhara et al., 2005; Sandeep et al.,
2007b). Moreover, serum visfatin levels were more associated with
visceral fat mass than subcutaneous fat mass and appear to vary
according to the body fat composition (Sun et al., 2007; Botella-
Carretero et al., 2008). More studies are required to investigate
their relationship.
Surprisingly, plasma visfatin concentrations were elevated after
bariatric surgery (Krzyzanowska et al., 2006; Garcia-Fuentes et al.,
2007; Botella-Carretero et al., 2008; Friebe et al., 2011). In one
study of 53 severely obese persons who underwent biliopancreatic
diversion (n= 38) and gastric bypass (n= 15), plasma visfatin lev-
els were significantly increased 7 months after the surgery, and they
were positively correlated with the percentage of waist circumfer-
ence reduction (Garcia-Fuentes et al., 2007). In another report,
there was an almost 50% increase in plasma visfatin levels post-
compared to pre-biliopancreatic or laparoscopic bariatric surgery.
In this study, multiple regression analysis showed that weight
loss, diabetic status, and waist circumference changes were the
main contributors to the increased serum visfatin levels (Botella-
Carretero et al., 2008). Overall, these results indicate that plasma
visfatin levels tend to be increased after weight loss surgeries
(Garcia-Fuentes et al., 2007; Botella-Carretero et al., 2008). Given
the well documented insulin-mimetic effect visfatin, the reason for
the increased visfatin levels after weight loss is unclear, but may
indicate a role for visfatin in improved insulin sensitivity after
weight loss surgeries.
RESISTIN
Resistin is mainly secreted by adipocytes and macrophages found
in visceral adipose tissue. Increased plasma resistin levels lead to
over-production of glucose from the liver and inhibit preadipocyte
differentiation; however the precise mechanisms are still unclear
(Steppan et al., 2001; Steppan and Lazar, 2002; Wolf, 2004). In rats,
resistin induces severe hepatic insulin resistance and increases glu-
cose production (Piestrzeniewicz et al., 2008). In human studies
the role of resistin in insulin resistance and glucose metabolism
is inconclusive (Lee et al., 2003; Qasim et al., 2008). The proin-
flammatory effects of resistin were attributed to its ability to
activate NF-kB signaling pathway and subsequently increase the
production of proinflammatory cytokines including TNF-α and
IL-6, both of which can impair insulin signaling pathways and
lead to insulin resistance (Zeyda and Stulnig, 2009; Singla et al.,
2010; Maenhaut and Van de Voorde, 2011). In addition, resistin
can activate SOCS-3 protein, which can lead to insulin resistance
(Steppan et al., 2005). Although some studies suggest a relationship
between resistin and glucose metabolism, others disagree (Sen-
tinelli et al., 2002; Lee et al., 2003; Iqbal et al., 2005). Moreover,
several studies reported that increased plasma resistin levels were
associated with increased BMI (Filkova et al., 2009; Moschen et al.,
2009).
Effects of bariatric surgery on plasma resistin levels are incon-
clusive. Some studies found that plasma resistin levels were sig-
nificantly decreased 12 months after bariatric surgery with >10%
loss of the excess body weight (Edwards et al., 2010; Jankiewicz-
Wika et al., 2011; Marantos et al., 2011). These studies also
reported that plasma resistin levels were positively correlated with
insulin resistance and glucose intolerance (Moschen et al., 2009;
De Luis et al., 2010; Jankiewicz-Wika et al., 2011; Marantos et al.,
2011). Other studies showed no difference in plasma resistin levels
after significant weight loss caused by bariatric surgery (Wolfe
et al., 2004; Iqbal et al., 2005). More studies are required to
investigate the relationship between plasma resistin levels and
weight loss.
APELIN
Apelin is a recently discovered peptide that is secreted by diverse
tissues including central nervous system, adipose, and many other
peripheral tissues, such as heart, kidneys, liver, and brain. Apelin
is a binding ligand for the orphan G-protein–coupled receptor
APJ (Yamamoto et al., 2011). A common 77-amino-acid precur-
sor produces three bioactive apelin, which contain 13 amino acids
(apelin-13), 17 amino acids (apelin-17), or 36 amino acids (apelin-
36), respectively (Beltowski, 2006; Reinehr et al., 2011). Animal
studies showed that apelin-deficient mice are insulin resistant and
develop hyperinsulinemia, which can be reversed by administra-
tion of exogenous apelin (Yue et al., 2010). Administration of
apelin to diabetic (db/db) obese mice can increase glucose uptake
and elevate insulin sensitivity (Dray et al., 2008; Yue et al., 2010).
Apelin stimulates PI3K/Akt phosphorylation-dependent GLUT 4
translocation, therefore increases glucose uptake by adipocytes
(Lee et al., 2006; Zhu et al., 2011). Furthermore, apelin secre-
tion can activate AMP-activated protein kinase (AMPK) pathway
and leading to an insulin sensitizing effect (Kadoglou et al., 2010;
Attane et al., 2011).
Apelin expression and secretion are increased during adipocyte
differentiation and are regulated nutritionally and hormonally
(Boucher et al., 2005; Dray et al., 2008). Type 2 diabetes subjects
have significantly higher plasma apelin levels than non-diabetic
healthy subjects. The increase in plasma apelin levels may be a
result of compensatory response to insulin resistance (Boucher
et al., 2005; Soriguer et al., 2009; Dray et al., 2010). Obese subjects
have significantly higher plasma apelin levels than lean subjects
(Boucher et al., 2005; Heinonen et al., 2005; Castan-Laurell et al.,
2011). Soriguer et al. (2009) demonstrated that the plasma apelin
levels were increased only in obese and diabetic subjects, not
in obese and non-diabetic subjects, as compared with control
subjects. This indicates that obesity and body fat mass may not be
the main factors altering circulating apelin levels (Boucher et al.,
2005), and insulin resistance may be more important than obe-
sity in increasing plasma apelin levels in humans. Although there
is a strong positive correlation between plasma apelin levels and
TNF-α expression in expanded adipose tissue, the role of apelin in
regulating inflammatory response is still not clear (Boucher et al.,
2005; Daviaud et al., 2006).
Plasma apelin levels can vary according to the diabetic status
after weight loss following the bariatric surgery. In a study, diabetic
morbidly obese patients had significantly higher plasma apelin lev-
els than non-diabetic non-obese healthy subjects. After bariatric
surgery, plasma apelin levels in morbidly obese subjects with
impaired blood glucose were significantly decreased (Soriguer
et al., 2009). Krist et al. (2013) also demonstrated that bariatric
surgery dramatically decreased the apelin expression in adipose
tissues and serum apelin levels, which significantly correlated
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with improved insulin sensitivity. This correlation is indepen-
dent of BMI changes. More studies are required to investigate the
underlying mechanisms.
VASPIN
Vaspin is a member of the serine protease inhibitor family and is
also known as visceral adipose-tissue derived serpin. But human
subcutaneous adipose tissue, liver, stomach, and rodent hypothal-
amus also express vaspin (Lee et al., 2011). Vaspin is also expressed
in adipose tissues in Otsuka Long-Evans Tokushima rats, which
are used as an animal model for studying type 2 diabetes (El-
Mesallamy et al., 2011). Studies suggest that vaspin may have
important roles in obesity and insulin resistance (Li et al., 2011).
Administration of vaspin to obese mice improved glucose tol-
erance and elevates insulin sensitivity (Hida et al., 2005; Wada,
2008). However, the underlying mechanisms of improving insulin
sensitivity are not known.
Some studies demonstrate that diabetic subjects have higher
serum vaspin levels than non-diabetic subjects (Ye et al., 2009;
Kempf et al., 2010). Lean subjects have lower serum vaspin lev-
els than overweight subjects (Suleymanoglu et al., 2009). Others
reported a positive association between blood vaspin levels and
BMI in obesity (Youn et al., 2008; Chang et al., 2010; Bluher, 2012).
Blood vaspin levels and BMI correlation is strong in type 2 diabetes
or insulin resistant patients. This indicates that obesity-induced
insulin resistance may be more important than BMI in regulat-
ing circulating vaspin levels (Youn et al., 2008; Chang et al., 2010;
Kempf et al., 2010). Since vaspin can improve glucose tolerance
and insulin sensitivity, the increase in plasma vaspin levels may be
a result of compensatory response to insulin resistance.
Weight loss decreases plasma vaspin levels in humans (Klot-
ing et al., 2006; Li et al., 2008; Youn et al., 2008). Weight loss
after bariatric surgery significantly decreases plasma vaspin lev-
els, which also correlates with decreased plasma insulin levels and
improved insulin sensitivity (Chang et al., 2010; Handisurya et al.,
2010). This decrease might be a compensatory mechanism asso-
ciated with weight loss and insulin sensitivity. Even though these
findings suggest that vaspin may have some roles in regulating glu-
cose metabolism and insulin signaling pathways, the mechanisms
are not yet understood (Kloting et al., 2006; Youn et al., 2008).
RETINOL BINDING PROTEIN-4
Retinol binding protein-4 (RBP-4) is secreted predominantly by
adipocytes and hepatocytes. In plasma, RBP-4 is the carrier pro-
tein of retinol and appears to relate to glucose metabolism and
insulin sensitivity (Esteve et al., 2009). Increased RBP-4 levels
lead to reduced glucose uptake by muscle cells through inhibiting
PI3K signaling pathway and serine phosphorylation of IRS1 (Wolf,
2007), followed by decreased insulin sensitivity. Some studies
demonstrated an inverse correlation between glucose transporter
4 (GLUT4) protein expression and plasma RBP-4 levels (Graham
et al., 2006; Esteve et al., 2009; Toruner et al., 2010). Decreased
GLUT4 expression is accompanied by increased RBP-4 secretion
in the adipose tissue of obese subjects and reduced GLUT4 expres-
sion can be caused by increased RBP-4 secretion (Yang et al., 2005).
In liver, RBP-4 stimulates the expression of phosphoenolpyruvate
carboxykinase (PEPCK) enzyme, a gluconeogenic enzyme that is
stimulated by glucagon and inhibited by insulin (Quinn and Yea-
gley, 2005), leading to impaired insulin signaling in hepatocytes
(Yang et al., 2005).
Most but not all of the findings suggest that plasma RBP-4 levels
are positively associated with body fat percentage and insulin resis-
tance (Janke et al., 2006; von Eynatten et al., 2007; Yao-Borengasser
et al., 2007; Bajzova et al., 2008; Gomez-Ambrosi et al., 2008).
Obese subjects have higher plasma RBP-4 levels than lean sub-
jects. Plasma RBP-4 levels are positively correlated with insulin
resistance in subjects with obesity, impaired glucose tolerance, or
type 2 diabetes (Graham et al., 2006). RBP-4 levels were signif-
icantly decreased following weight loss after a bariatric surgery
(Haider et al., 2007; Gomez-Ambrosi et al., 2008; Tschoner et al.,
2008). Barazzoni et al. (2011) showed that high plasma RBP-4 lev-
els was correlated with high systemic inflammatory responses in
non-obese, non-diabetic patients with chronic kidney disease (But
the correlation was independent of RBP-4 expression in adipose
tissue. More studies are required to investigate the roles of RBP-4
in inflammation.
OTHER CHANGES IN GASTROINTESTINAL SYSTEM AFTER
BARIATRIC SURGERY
After a meal, gastrointestinal system secretes incretins includ-
ing glucose dependent insulinotropic polypeptide (GIP) and
glucagon-like peptide 1 (GLP-1), which stimulate post-prandial
insulin secretion (Holst, 2013; Holst and Deacon, 2013). GIP is
secreted by duodenal K cells and GLP-1 is secreted by ileal L
cells (Holst, 2013). These incretins have insulinotropic effects, fur-
thermore; GLP-1 delays gastric emptying and decreases appetite
leading to increased weight loss and insulin sensitivity (Flint et al.,
2001; Laferrère, 2011). GLP-1 is increased after Roux-en-Y gas-
tric bypass and biliopancreatic diversion (Näslund et al., 1997,
1998). Even though inconclusive findings on effects of the bariatric
surgery on blood GIP levels are reported (Näslund et al., 1998;
Laferrère, 2011, 2012), Laferrère et al. (2007) showed increased
blood GIP levels 1 month and 1 year after Roux-en-Y surgery in
patients with type 2 diabetes. Näslund et al. (1997) reported that
the increase in blood GLP-1 and GIP levels is persistent for 20 years
after duodenal jejunal bypass. More studies are required to inves-
tigate the effects of GLP-1 and GIP changes on inflammation in
obese subjects following bariatric surgery.
There are two hypotheses trying to explain the increase in
incretins secretion; foregut; and hindgut hypotheses (Strader et al.,
2005; Strader, 2006; Pacheco et al., 2007; Hansen et al., 2011;
de Luis et al., 2012). Foregut hypothesis suggests that bypass-
ing duodenum and proximal jejunum increases incretin secretion
which improves insulin sensitivity more than weight loss itself
(Pacheco et al., 2007; Hansen et al., 2011; de Luis et al., 2012).
However, research studies in Roux-en-Y gastric bypass and vertical
sleeve gastrectomy which does not bypass duodenum or jejunum
reported similar incretin secretion levels, therefore invalidating the
foregut hypothesis (Chambers et al., 2011). Hindgut hypothesis
suggests that instant stimulation of ileum by the nutrients causes
the increase in blood GLP-1 levels (Strader et al., 2005; Strader,
2006). After Roux-en-Y gastric bypass, emptying of the stomach is
fast and nutrients reach to ileum rapidly which might be the cause
of increased GLP-1 secretion (Morínigo et al., 2006).
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Bariatric surgery alters gut microbiota dramatically (Zhang
et al., 2009; Furet et al., 2010; Clément, 2011; Kootte et al., 2012;
Sweeney and Morton, 2013). Zhang et al. (2009) showed a pos-
itive association between Archaea and obesity. They found no
Archaea in normal weight subjects and a decreased number in
subjects who underwent gastric bypass surgery. Furet et al. (2010)
demonstrated a decrease in Prevotellacaea during obesity, but
the number of Prevotellacaea was rapidly increased after gastric
bypass surgery. Zhang et al. showed obese subjects had more Bac-
teroidetes than lean subjects. Contrary to Furet et al. findings,
Prevotellacaea, which is a subgroup of Bacteroidetes, was enriched
in obese subjects. Furthermore, Ley et al. (2006) found no dif-
ference in the amount of Bacteroidetes between lean and obese
subjects. These inconclusive data indicate that weight loss might be
affecting subgroups differently. Effects of gut microbiota changes
after bariatric surgery on inflammation, insulin resistance, and
diabetes are not completely understood (Kootte et al., 2012). How-
ever, even though there might be positive effect of gut microbiota
change on insulin sensitivity, this effect probably is overridden by
possible malnutrition state after bariatric surgeries (Kootte et al.,
2012).
CONCLUSION AND FUTURE DIRECTIONS
Obesity is a chronic low-grade inflammatory disease. In adipose
tissue, both adipocytes and macrophages secrete a large number
of hormones, proteins, cytokines, and chemokines, collectively
called adipokines. These adipokines contribute to the pathogenesis
of metabolic syndrome, insulin resistance, type 2 diabetes, and
cardiovascular disease, most likely via regulating the inflamma-
tory pathway mediated by TNF-α, IL-6, NF-kB, JNK, and IKK
and insulin signaling pathway mediated by IRSs, PI3k/Akt, and
SOCSs. Weight loss via surgeries dramatically alters levels of
these adipokines and overall increases insulin sensitivity. However,
despite ample evidence supporting the role of these adipokines in
obesity and insulin resistance, mechanisms mediating their effects
are for the most part still unclear. It is also unclear whether or
how these adipokines mediate the effect of weight loss surgeries
such as bariatric surgery on inflammation and insulin response.
Further studies are required to better understand the relationship
between those adipokines and insulin resistance and how these
are modulated by bariatric surgery. Alteration in the adipokine
profile primarily reflects changes in adipose-tissue production
and secretion of these cytokines. Thus, additional studies are
needed to determine whether reduced adipose-tissue inflamma-
tion following bariatric surgery is responsible for reduced systemic
inflammation and improved insulin sensitivity. Furthermore, the
development of animal models which recapitulate the bariatric
surgery model will lead to a better understanding of mechanisms
by which this surgery improves metabolic outcomes related to dia-
betes and obesity. It is especially important to understand whether
the beneficial effects of bariatric surgery are solely related to weight
loss, improved adipose-tissue inflammation and/or changes in gut
physiology and endocrinology. In addition, with an adequately
powered sample sizes for cross-sectional or case-control stud-
ies, the various types of adipose tissues, including subcutaneous,
omental, and mesenteric adipose tissues, along with plasma and
other tissues, can be collected from severely obese patients who
undergo bariatric surgery. Finally, long term studies are criti-
cal to assess whether weight loss surgery and associated meta-
bolic improvements are sustained over a long period of time
and whether these are primarily related to weight loss or other
beneficial effects of the bariatric surgery.
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